Journal Publications
Peer-reviewed publication of trial results in journals such as NEJM or The Lancet — the definitive, fully-vetted dataset behind a catalyst.
No Upcoming Journal Publications
There are no pending journal publications at this time.
About Journal Publications
Publication catalysts are the appearance of trial results in peer-reviewed journals — The New England Journal of Medicine, The Lancet, JAMA and others. Publication delivers the fully-vetted dataset, complete with methodology and independent review, that the market has often only seen in topline or conference form.
While the headline is usually already known, publication can still matter: it confers scientific credibility, is required for guideline inclusion and reimbursement, and occasionally surfaces details that shift the narrative.
Why Publications matter to investors
A high-profile publication cements the credibility of a dataset and is a prerequisite for clinical-guideline adoption and payer coverage — commercial tailwinds that outlast the initial catalyst. For contested results, the peer-reviewed detail can either settle or reignite the debate.
Frequently asked questions
Why is a journal publication a catalyst if the data is already known?
Publication provides the peer-reviewed, complete dataset, confers credibility, and is often required for treatment-guideline inclusion and insurance reimbursement — commercial factors that matter beyond the headline.
Which journals matter most for biotech?
The most influential are The New England Journal of Medicine (NEJM), The Lancet, and JAMA, along with leading specialty journals in the relevant disease area.
Can a publication move a stock?
It can, especially when the full data differs from the topline narrative or when publication unlocks guideline and reimbursement pathways.